Naringenin

Name: Naringenin
Brand: MedChemExpress
SKU: HY-N0100
Rating: 5.0 (22 reviews)

製品番号: HY-N0100 純度: 99.28%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Naringenin is the predominant flavanone in Citrus reticulata Blanco; displays strong anti-inflammatory and antioxidant activities. Naringenin has anti-dengue virus (DENV) activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 480-41-1

容量	価格（税別）	在庫状況	数量

>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$50	在庫あり	Estimated Time of Arrival: December 31
10 mg	$60	在庫あり	Estimated Time of Arrival: December 31
50 mg	$96	在庫あり	Estimated Time of Arrival: December 31
100 mg	$115	在庫あり	Estimated Time of Arrival: December 31
250 mg	$230	在庫あり	Estimated Time of Arrival: December 31
500 mg	$322	在庫あり	Estimated Time of Arrival: December 31
1 g	$420	在庫あり	Estimated Time of Arrival: December 31
5 g		お問い合わせ
10 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 22 publication(s) in Google Scholar

Other Forms of Naringenin:

Naringenin-d₄ 在庫あり
(±)-Naringenin 在庫あり

顧客検証

Histological Imaging/Staining

In Vivo Efficacy Study

Bio/Physico-chemical Assay

IHC

: Naringenin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep:132:155886. [Abstract]; Naringenin (100 mg/kg/d, i.g.). HE staining, Oil red staining in the liver.

: Naringenin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep:132:155886. [Abstract]; Naringenin (100 mg/kg/d, i.g.). The appearance of gallstones of mice in different treatment groups.

: Naringenin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep:132:155886. [Abstract]; The naringenin l group and the naringenin H group were treated with naringenin (50 mg/kg/d, i.g.) and naringenin (100 mg/kg/d, i.g.). CGS column chart for mice.

: Naringenin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep:132:155886. [Abstract]; The naringenin l group and the naringenin H group were treated with naringenin (50 mg/kg/d, i.g.) and naringenin (100 mg/kg/d, i.g.). WB results and statistical analysis bar graphs of HMGCR, UGT1A1, and SOAT2 (n = 6).

: Naringenin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep:132:155886. [Abstract]; The naringenin l group and the naringenin H group were treated with naringenin (50 mg/kg/d, i.g.) and naringenin (100mg/kg/d, i.g.). Levels of ALT and AST in serum.

: Naringenin purchased from MedChemExpress. Usage Cited in: J Funct Foods. 2020 Jun.; Naringenin decreases the number of Iba-1-positive microglia and fully-activated microglia. Schematic diagram of the selected region of brain section for immunochemistry and Representative Iba-1 staining.

: Naringenin purchased from MedChemExpress. Usage Cited in: J Funct Foods. 2020 Jun.; Naringenin prevents the neuroinflammation. Representative Western blot bands of TNF-α, IL-1β, IL-6, IL-10, and iNOS.

PPAR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

PPARα PPARβ/δ PPARγ PPAR PPARδ

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Human Endogenous Metabolite Microbial Metabolite

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Naringenin is the predominant flavanone in Citrus reticulata Blanco; displays strong anti-inflammatory and antioxidant activities. Naringenin has anti-dengue virus (DENV) activity.

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 100 μM Compound: 4	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18440233]
B16-BL6	IC₅₀	> 100 μM Compound: 4	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 18440233]
BJ	EC₅₀	> 10 μM Compound: 2	Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
C8166	CC₅₀	141.6 μg/mL Compound: 6	Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24794743]
C8166	EC₅₀	9.47 μg/mL Compound: 6	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis	[PMID: 24794743]
CCRF-CEM	EC₅₀	> 10 μM Compound: 2	Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
Col2	EC₅₀	> 1 x 10³ nM Compound: naringenin	Cytotoxicity against human Col2 cells Cytotoxicity against human Col2 cells	[PMID: 15043407]
DLD-1	IC₅₀	> 25 μM Compound: 9	Cytotoxicity against human DLD1 cells Cytotoxicity against human DLD1 cells	[PMID: 18039011]
H9	EC₅₀	92 μM Compound: 19	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	294 μM Compound: 19	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
HEK293	IC₅₀	14.4 μM Compound: 12	Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol	[PMID: 18533708]
HEK293	IC₅₀	4.96 μM Compound: 12	Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol	[PMID: 18533708]
HL-60	IC₅₀	413.7 μM Compound: Naringenin	Cytotoxicity against human HL60 cells after 46 hrs by MTT assay Cytotoxicity against human HL60 cells after 46 hrs by MTT assay	[PMID: 23756061]
HSC-2	CC₅₀	0.55 mM Compound: 19	Cytotoxicity against human HSC2 cells Cytotoxicity against human HSC2 cells	[PMID: 11170668]
HT-1080	IC₅₀	> 100 μM Compound: 4	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 18440233]
HUVEC	ED₅₀	> 1 x 10³ nM Compound: naringenin	Cytotoxicity against HUVEC Cytotoxicity against HUVEC	[PMID: 15043407]
HeLa	EC₅₀	> 10 μM Compound: 2	Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
HeLa	IC₅₀	> 100 μM Compound: 4	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18440233]
HeLa	IC₅₀	> 25 μM Compound: 9	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 18039011]
Jurkat	IC₅₀	41.6 μM Compound: Naringenin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method	[PMID: 30776692]
Jurkat	IC₅₀	48.8 μM Compound: Naringenin	Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method	[PMID: 30776692]
KB	ED₅₀	2.71 μg/mL Compound: narigenin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 8450317]
KB	ED₅₀	> 1 x 10³ nM Compound: naringenin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 15043407]
L5178Y	IC₅₀	>= 11.3 μM Compound: 1	Cytotoxicity against multi-drug resistant mouse L5178Y cells transfected with ABCB1 gene assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against multi-drug resistant mouse L5178Y cells transfected with ABCB1 gene assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 33038666]
L5178Y	IC₅₀	>= 11.3 μM Compound: 1	Cytotoxicity against parental mouse L5178Y cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against parental mouse L5178Y cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 33038666]
LNCaP	ED₅₀	> 1 x 10³ nM Compound: naringenin	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 15043407]
Lu1	ED₅₀	> 1 x 10³ nM Compound: naringenin	Cytotoxicity against human Lu1 cells Cytotoxicity against human Lu1 cells	[PMID: 15043407]
MCF7	EC₅₀	> 10 μM Compound: 2	Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
MCF7	IC₅₀	0.3 μM Compound: Naringenin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MCF7	IC₅₀	5.1 μM Compound: Naringenin	Inhibition of aromatase in human MCF7 cells using [1beta-3H]androstenedione as substrate measured after 1 hr by liquid scintillation counting method Inhibition of aromatase in human MCF7 cells using [1beta-3H]androstenedione as substrate measured after 1 hr by liquid scintillation counting method	[PMID: 27155469]
NALM-6	IC₅₀	426.3 μM Compound: Naringenin	Cytotoxicity against human NALM6 cells after 46 hrs by MTT assay Cytotoxicity against human NALM6 cells after 46 hrs by MTT assay	[PMID: 23756061]
Neutrophil	IC₅₀	3.3 μM Compound: 66	Inhibition of fMLF/CB-induced human Neutrophil activation assessed as reduction in superoxide anion Inhibition of fMLF/CB-induced human Neutrophil activation assessed as reduction in superoxide anion	[PMID: 37683361]
Neutrophil	IC₅₀	5.3 μM Compound: 66	Inhibition of fMLF/CB-induced human Neutrophil activation assessed as reduction in elastase release Inhibition of fMLF/CB-induced human Neutrophil activation assessed as reduction in elastase release	[PMID: 37683361]
PLC-PRF-5	ED₅₀	2.47 μg/mL Compound: narigenin	Cytotoxicity against human PLC/PRF/5 cells Cytotoxicity against human PLC/PRF/5 cells	[PMID: 8450317]
RAW264.7	IC₅₀	60 μM Compound: 11	Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs	[PMID: 27955927]
RPMI-8226	EC₅₀	> 10 μM Compound: 2	Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
TERT-RPE1	ED₅₀	> 1 x 10³ nM Compound: naringenin	Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells	[PMID: 15043407]
THP-1	EC₅₀	> 10 μM Compound: 2	Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method	[PMID: 20192247]
THP-1	IC₅₀	> 10 μM Compound: 25	Cytotoxicity against human THP1 cells assessed as cell viability after 24 hrs by WST assay Cytotoxicity against human THP1 cells assessed as cell viability after 24 hrs by WST assay	[PMID: 25735399]
U-266	EC₅₀	> 10 μM Compound: 2	Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
WM-115	IC₅₀	524.8 μM Compound: Naringenin	Cytotoxicity against human WM115 cells after 46 hrs by MTT assay Cytotoxicity against human WM115 cells after 46 hrs by MTT assay	[PMID: 23756061]

体外実験

Naringenin is shown to inhibit the proliferation of HepG2 cells resulted partly from an accumulation of cells in the G0/G1 and G2/M phase of the cell cycle. Naringenin has been shown to induce apoptosis as evidenced by nuclei damage and increased proportion of apoptotic cells. Naringenin triggers the mitochondrial-mediated apoptosis pathway as shown by an increased ratio of Bax/Bcl-2, subsequent release of cytochrome C, and sequential activation of caspase-3^[1]. Naringenin exposure significantly reduces the cell viability of A431 cells with a concomitant increase in nuclear condensation and DNA fragmentation in a dose dependent manner. Cell cycle study shows that naringenin induced cell cycle arrest in G0/G1 phase of cell cycle and caspase-3 analysis reveal a dose dependent increment in caspase-3 activity which leads to cell apoptosis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Naringenin supplementation causes a significant reduction in the amount of total triglyceride and cholesterol in plasma and liver. In addition, naringenin supplementation lowers adiposity and triglyceride contents in parametrial adipose tissue. Naringenin-fed animals show a significant increase in PPARα protein expression in the liver. The expression of CPT-1 and UCP2, known to be regulated by PPARα, is markedly enhanced by naringenin treatment^[3]. Naringenin increases hepatic fatty acid oxidation through a PPARγ coactivator 1α/PPARα-mediated transcription program. It prevents sterol regulatory element-binding protein 1c–mediated lipogenesis in both liver and muscle by reducing fasting hyperinsulinemia. Naringenin decreases hepatic cholesterol and cholesterol ester synthesis^[4]. Naringenin inhibits TNF-α-induced VSMC proliferation and migration in a dose-dependent manner. Mechanistic study demonstrates that naringenin prevents ERK/MAPK and Akt phosphorylation while left p38 MAPK and JNK unchanged. Naringenin also blocks the increase of ROS generation induced by TNF-α^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

分子量

272.25

分子式

C₁₅H₁₂O₅

CAS 番号

480-41-1

Appearance

Solid

Color

White to light yellow

SMILES

O=C1C[C@@H](C2=CC=C(O)C=C2)OC3=CC(O)=CC(O)=C13

Structure Classification

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (367.31 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.6731 mL	18.3655 mL	36.7309 mL
5 mM	0.7346 mL	3.6731 mL	7.3462 mL
10 mM	0.3673 mL	1.8365 mL	3.6731 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.28%

Select Batch:

データシート (280 KB) SDS (393 KB)

COA (247 KB) HNMR (272 KB) RP-HPLC (282 KB) LCMS (95 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Arul D, et al. Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Pathol Oncol Res. 2013 Oct;19(4):763-70. [Content Brief]

[2]. Ahamad MS, et al. Induction of apoptosis and antiproliferative activity of naringenin in human epidermoid carcinomacell through ROS generation and cell cycle arrest. PLoS One. 2014 Oct 16;9(10):e110003. [Content Brief]

[3]. Cho KW, et al. Dietary naringenin increases hepatic peroxisome proliferators-activated receptor α proteinexpression and decreases plasma triglyceride and adiposity in rats. Eur J Nutr. 2011 Mar;50(2):81-8. [Content Brief]

[4]. Mulvihill EE, et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDLreceptor-null mice with diet-induced insulin resistance. Diabetes. 2009 Oct;58(10):2198-210. [Content Brief]

[5]. Chen S, et al. Naringenin inhibits TNF-α induced VSMC proliferation and migration via induction of HO-1. Food Chem Toxicol. 2012 Sep;50(9):3025-31. [Content Brief]

[6]. Frabasile S, et al. The citrus flavanone naringenin impairs dengue virus replication in human cells. Sci Rep. 2017 Feb 3;7:41864. [Content Brief]

細胞実験 ^[1]	Naringenin is dissolved in DMSO and diluted in cell culture medium. The cells are rinsed with PBS and grown in a medium containing various concentrations of naringenin (50, 100, 150, 200, 250, 300 μM). The solvent DMSO treated cells are served as control. After 24 hrs of treatment, the medium is removed and replaced by another medium containing MTT. Cell viability is measured using the MTT assay^[1]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
動物実験 ^[3]^[4]	Rats: Semi-purified, powdered diets are prepared for concentrations of naringenin: 0, 0.003, 0.006, and 0.012% of diet. After 7 days of acclimatization, rats are assigned to one of four groups, with six animals per group, and fed semi-purified experimental diets for 6 weeks. The experimental diets contain 16% fat, 45.5% sucrose, and different naringenin concentration (0, 0.003, 0.006, or 0.012%) (Table 1). Rats have ad libitum access to food and water during the study period. Food intake and body weight are measured throughout the experiment^[3]. Mouse: Eight- to 12-week-old mice are fed ad libitum a rodent standard diet or a high-fat diet containing 42% of calories from fat plus cholesterol (0.05% wt/wt). Naringenin is added to the Western diet at 1 or 3% (wt/wt). Ldlr^−/− mice are fed for 4 weeks and C57BL/6J mice for 30 weeks. Food intake is measured daily, and body weight is measured biweekly. Mice are fasted for 6 h before intervention^[4]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
参考文献	[1]. Arul D, et al. Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Pathol Oncol Res. 2013 Oct;19(4):763-70. [Content Brief] [2]. Ahamad MS, et al. Induction of apoptosis and antiproliferative activity of naringenin in human epidermoid carcinomacell through ROS generation and cell cycle arrest. PLoS One. 2014 Oct 16;9(10):e110003. [Content Brief] [3]. Cho KW, et al. Dietary naringenin increases hepatic peroxisome proliferators-activated receptor α proteinexpression and decreases plasma triglyceride and adiposity in rats. Eur J Nutr. 2011 Mar;50(2):81-8. [Content Brief] [4]. Mulvihill EE, et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDLreceptor-null mice with diet-induced insulin resistance. Diabetes. 2009 Oct;58(10):2198-210. [Content Brief] [5]. Chen S, et al. Naringenin inhibits TNF-α induced VSMC proliferation and migration via induction of HO-1. Food Chem Toxicol. 2012 Sep;50(9):3025-31. [Content Brief] [6]. Frabasile S, et al. The citrus flavanone naringenin impairs dengue virus replication in human cells. Sci Rep. 2017 Feb 3;7:41864. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.6731 mL	18.3655 mL	36.7309 mL	91.8274 mL
	5 mM	0.7346 mL	3.6731 mL	7.3462 mL	18.3655 mL
	10 mM	0.3673 mL	1.8365 mL	3.6731 mL	9.1827 mL
	15 mM	0.2449 mL	1.2244 mL	2.4487 mL	6.1218 mL
	20 mM	0.1837 mL	0.9183 mL	1.8365 mL	4.5914 mL
	25 mM	0.1469 mL	0.7346 mL	1.4692 mL	3.6731 mL
	30 mM	0.1224 mL	0.6122 mL	1.2244 mL	3.0609 mL
	40 mM	0.0918 mL	0.4591 mL	0.9183 mL	2.2957 mL
	50 mM	0.0735 mL	0.3673 mL	0.7346 mL	1.8365 mL
	60 mM	0.0612 mL	0.3061 mL	0.6122 mL	1.5305 mL
	80 mM	0.0459 mL	0.2296 mL	0.4591 mL	1.1478 mL
	100 mM	0.0367 mL	0.1837 mL	0.3673 mL	0.9183 mL

Naringenin Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Naringenin480-41-1Dengue VirusPPARReactive Oxygen Species (ROS)Influenza VirusEndogenous MetaboliteDENVPeroxisome proliferator-activated receptorsInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Naringenin

カスタマーレビュー

Other Forms of Naringenin:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

PPAR アイソフォーム固有の製品をすべて表示:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Naringenin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Naringenin

カスタマーレビュー

Other Forms of Naringenin:

Naringenin 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

PPAR アイソフォーム固有の製品をすべて表示:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Naringenin 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Naringenin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report